目的:本研究旨在确定沙特阿拉伯镰状细胞病(SCD)的直接和间接成本。
方法:数据来自沙特阿拉伯东部地区217名年龄≥18岁的参与者,使用基于患病率的疾病成本方法。医疗技术评估研究所医疗消费问卷和医疗技术评估研究所生产力成本问卷用于评估成本。使用了多级过程,包括3个月以上的患者数据收集,根据诊所就诊和药品价格计算成本,以及年度估计的外推。
结果:该研究揭示了SCD的巨大社会成本,平均每位患者的费用为181.899瑞士法郎(48.506美元),涵盖医疗保健和生产力损失。医疗费用,包括住院,非正式护理,和药物,平均80.306里亚尔(21.415美元)。此外,生产力成本,包括无偿工作和出勤,平均SAR101.594(27.092美元)。获得更高水平的教育,如文凭和学士学位或更高学位,已发现显着降低与SCD相关的成本(P=.016,P=.001)。此外,当比较不同的就业状态时,学生(B=-0.301,P=0.058)被发现SCD成本略低,这表明他们的支出低于其他就业类别的个人。本研究中使用的预测模型解释了11.2%的成本变化。
结论:我们的研究强调了沙特阿拉伯SCD的重大经济负担,并强调需要有针对性的策略来缓解财务挑战并改善患者的健康状况。
OBJECTIVE: This study aimed to determine the direct and indirect costs of sickle cell disease (SCD) in Saudi Arabia.
METHODS: Data were collected from 217 participants aged ≥18 years in the eastern region of Saudi Arabia, using a prevalence-based cost-of-illness approach. The Institute for Medical Technology Assessment Medical Consumption Questionnaire and Institute for Medical Technology Assessment Productivity Cost Questionnaire were used to assess costs. A multistage process was used, encompassing patient data collection over 3 months, cost calculation from clinic visits and drug prices, and extrapolation for annual estimates.
RESULTS: The study revealed substantial societal costs of SCD, with an average per-patient cost of SAR181 899 (US$48 506), covering healthcare and productivity losses. Healthcare costs, including hospitalization, informal care, and medication, averaged SAR80 306 (US$21 415). In addition, productivity costs, including unpaid work and presenteeism, averaged SAR101 594 (US$27 092). Obtaining higher levels of education, such as a diploma and BSc degree or higher, has been found to significantly decrease the costs associated with SCD (P = .016, P = .001). Furthermore, when comparing different employment statuses, students (B = -0.301, P = .058) were found to have marginally lower SCD costs, suggesting that their expenses were lower than those of individuals in other employment categories. The predictive model used in this study explained 11.2% of the variation in costs.
CONCLUSIONS: Our study highlights a significant economic burden of SCD in Saudi Arabia and highlights the need for targeted strategies to alleviate financial challenges and improve patient well-being.